Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
VVOS vs BVS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BVS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)
BVS Overall Winner
6-Pillar Tally: VVOS 0 – 6 BVS
Matrix Metrics: VVOS 1 – 9 BVS
As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas BVS carries 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin).
- Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. VVOS 36.4/100 SELL) and 0.85β · 74% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile BVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About VVOS vs BVS
VVOS
Vivos Therapeutics, Inc. Common Stock
$0.05
-5.1% 1D
Market Cap
$1.9M
TTM Revenue
$21M
Forward P/E
N/M
Beta / 30D Vol
1.70β · 111% Vol
Unified Composite Score
36.4
SELL
Tech 25.0
Fund 35.0
Flow 50.0
Mom 30.0
Weinstein Technical Phase
Markdown · Sell / avoid
BVS
Head-to-Head Winner
Bioventus Inc. Class A Common Stock
$9.88
-0.7% 1D
Market Cap
$681.3M
TTM Revenue
$586M
Forward P/E
11.1x
Beta / 30D Vol
0.85β · 74% Vol
Unified Composite Score
46.2
HOLD
Tech 35.0
Fund 49.0
Flow 64.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (VVOS 0 – 6 BVS)
1. Valuation Multiples
BVS
Forward P/E
N/M
11.1x
Trailing P/E
N/M
12.3x
PEG Ratio
N/M
1.20x
EV / Revenue
0.1x
1.5x
2. Growth & Scale
BVS
Revenue Growth (YoY)
+34.9%
+2.7%
Earnings Growth (YoY)
+0.0%
+69.7%
TTM Revenue (USD)
$21M
$586M
Market Cap
$1.9M
$681.3M
3. Profitability & Quality
BVS
Gross Margin
61.9%
68.7%
Operating Margin
-107.9%
10.1%
Net Profit Margin
-121.8%
9.8%
Return on Equity (ROE)
-8585.3%
25.8%
4. Balance Sheet & Cash Flow
BVS
Cash Generation (TTM)
-$21M EBITDA
$85M
Cash Flow Margin
-99.3% EBITDA Mgn
14.5%
Net Cash / Leverage
-8585.3% ROE
$199M Net Debt (0.96x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
BVS
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
N/A (N/A)
448.1% (100th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
BVS
OpEx & R&D Intensity
N/A
58.6% of Rev ($343M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: VVOS (1) vs BVS (9)| Institutional Metric | VVOS | BVS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.9M | $681.3M | BVS | |
| Trailing P/E Ratio | N/M | 12.3x | BVS | |
| Forward P/E Ratio | N/M | 11.1x | BVS | |
| Revenue Growth (YoY) | +34.9% | +2.7% | VVOS | |
| Operating Margin (TTM) | -107.9% | 10.1% | BVS | |
| Net Profit Margin | -121.8% | 9.8% | BVS | |
| Return on Equity (ROE) | -8585.3% | 25.8% | BVS | |
| 52-Week Range Position | 0% ($0–$3) | 36% ($6–$16) | BVS | |
| Beta / 30D Volatility | 1.70β · 111% Vol | 0.85β · 74% Vol | BVS | |
| Unified Institutional Score | 36.4 / 100 (SELL) | 46.2 / 100 (HOLD) | BVS | |
| Trailing 12M Revenue (USD) | $21M | $586M | Scale | |
| Gross Profit Margin (TTM) | 61.9% | 68.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.1x EV/Rev | 1.20x PEG · 1.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$21M EBITDA (-8585.3% ROE) | $85M ($199M Net Debt (0.96x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BVS +24.94 pp
3M Horizon
BVS +50.96 pp
6M Horizon
BVS +97.62 pp
1Y Horizon
BVS +144.73 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VVOS Revenue | BVS Revenue | VVOS Op. Margin | BVS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $340M | -92.8% | 9.2% | BVS |
| FY2020 | $10M | $320M | -92.1% | 6.6% | BVS |
| FY2021 | $20M | $430M | -120.7% | 2.8% | BVS |
| FY2022 | $20M | $510M | -156.2% | -32.7% | BVS |
| FY2023 | $10M | $510M | -125.3% | -16.0% | BVS |
| FY2024 | $20M | $570M | -74.3% | -2.7% | BVS |
| FY2025 | $20M | $570M | -114.1% | 9.5% | BVS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
VVOS
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BVS
BREAKDOWN
Current IV
448.1%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact BVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
VVOS Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
BVS Moat Profile
Scale & Operating Efficiency Moat
Medical Devices Operator
OpEx & R&D Reinvestment
58.6% of Rev ($343M)
90D Engineering Disclosures
0 Published
Investor FAQ VVOS vs BVS Key Questions & Quantitative Answers
As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas BVS carries 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin). Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. VVOS 36.4/100 SELL) and 0.85β · 74% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile BVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BVS leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with BVS at +2.7% YoY revenue growth and +69.7% YoY earnings growth on $586M TTM revenue (68.7% gross margin, 10.1% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), VVOS cumulative revenue shifted +100.0% while BVS shifted +67.6%. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus 58.6% of Rev ($343M) (0 disclosures) for BVS.
BVS screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas BVS trades at 11.1x Forward P/E, 12.3x Trailing P/E, 1.20x PEG, and 1.5x EV/Revenue (14.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus BVS (25.8% ROE) capital efficiency.
In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, BVS carries 448.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 74% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BVS vs VVOS · Reverse Pair
BVS vs AVAH
· Sector Peer
BVS vs ANNX
· Sector Peer
BVS vs TMCI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking